Dendritic cells naturally reside in the skin, making intradermal administration a natural and logical route of administration. Compared to other routes of administration (e.g., IV), intradermal administration enables Dendritic Cells to efficiently traffic to the lymph nodes, where they initiate an immune response.
Alternatively, cell-based therapies are increasingly being utilized for dermatological conditions, where intradermal delivery is, therefore, the most logical ROA for some of these applications, offering targeted delivery to the disease site.
For cell therapies to be effective, large numbers of viable cells must be delivered to the target site. Current injection methods can damage sensitive cells due to high injection pressures/ shear stress. Additionally, alternative methods, such as IV infusion deliver high volumes of cells to compensate for the expected loss in cell numbers.
Our technology is fully optimized for cell-based therapies, offering a unique set of advantages that make it particularly well-suited for these applications:
